$1.43
-0.11-7.14%
At close: -
$1.43
-0.00470-0.33%
After Hours: 6:10 PM EDT
Comments
Loading...
ProQR Therapeutics Analyst Ratings and Price Targets | NASDAQ:PRQR | Benzinga
ProQR Therapeutics NV has a consensus price target of $7.93 based on the ratings of 7 analysts. The high is $14 issued by Raymond James on October 29, 2024. The low is $2 issued by Citigroup on April 18, 2024. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and Jones Trading on March 14, 2025, March 14, 2025, and February 12, 2025, respectively. With an average price target of $9 between Chardan Capital, HC Wainwright & Co., and Jones Trading, there's an implied 531.45% upside for ProQR Therapeutics NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
HC Wainwright & Co.
Jones Trading
JMP Securities
Raymond James
1calculated from analyst ratings
Analyst Ratings for ProQR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/14/2025 | Buy Now | 180.64% | Chardan Capital | Keay Nakae54% | $4 → $4 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | 741.93% | HC Wainwright & Co. | Andrew Fein56% | $10 → $12 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 671.77% | Jones Trading | Catherine Novack28% | → $11 | Initiates | → Buy | Get Alert |
| 12/12/2024 | Buy Now | 461.29% | JMP Securities | Jonathan Wolleben67% | $8 → $8 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/12/2024 | Buy Now | 180.64% | Chardan Capital | Keay Nakae54% | $4 → $4 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | 601.61% | HC Wainwright & Co. | Andrew Fein56% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 601.61% | HC Wainwright & Co. | Andrew Fein56% | $5 → $10 | Maintains | Buy | Get Alert |
| 10/29/2024 | Buy Now | 882.25% | Raymond James | Steven Seedhouse58% | $6 → $14 | Upgrade | Outperform → Strong Buy | Get Alert |
| 05/10/2024 | Buy Now | 250.8% | HC Wainwright & Co. | Andrew Fein56% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 75.4% | Chardan Capital | Keay Nakae54% | $2.5 → $2.5 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 40.32% | Citigroup | Yigal Nochomovitz56% | $1.8 → $2 | Maintains | Neutral | Get Alert |
| 03/14/2024 | Buy Now | 250.8% | HC Wainwright & Co. | Andrew Fein56% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 75.4% | Chardan Capital | Keay Nakae54% | $2 → $2.5 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 180.64% | Raymond James | Steven Seedhouse58% | $5 → $4 | Maintains | Outperform | Get Alert |
| 11/08/2023 | Buy Now | 40.32% | Chardan Capital | Keay Nakae54% | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 09/18/2023 | Buy Now | 26.29% | Citigroup | Yigal Nochomovitz56% | $2.1 → $1.8 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 250.8% | HC Wainwright & Co. | Andrew Fein56% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 40.32% | Chardan Capital | Keay Nakae54% | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/26/2023 | Buy Now | 47.34% | Citigroup | Yigal Nochomovitz56% | $2.25 → $2.1 | Maintains | Neutral | Get Alert |
| 05/17/2023 | Buy Now | 215.72% | Cantor Fitzgerald | Jennifer Kim46% | $5 → $4.5 | Maintains | Overweight | Get Alert |
| 05/17/2023 | Buy Now | 320.96% | JMP Securities | Jonathan Wolleben67% | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/17/2023 | Buy Now | 250.8% | HC Wainwright & Co. | Andrew Fein56% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/30/2023 | Buy Now | 320.96% | JMP Securities | Jonathan Wolleben67% | → $6 | Reiterates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | 250.8% | HC Wainwright & Co. | Andrew Fein56% | $1.5 → $5 | Maintains | Buy | Get Alert |
| 12/23/2022 | Buy Now | 250.8% | Raymond James | Steven Seedhouse58% | $2 → $5 | Maintains | Outperform | Get Alert |
| 12/22/2022 | Buy Now | 250.8% | Cantor Fitzgerald | Jennifer Kim46% | $0.8 → $5 | Upgrade | Neutral → Overweight | Get Alert |
| 08/15/2022 | Buy Now | 5.24% | HC Wainwright & Co. | Andrew Fein56% | $2 → $1.5 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | — | Chardan Capital | Keay Nakae54% | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2022 | Buy Now | 40.32% | Raymond James | Steven Seedhouse58% | → $2 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/09/2022 | Buy Now | 40.32% | HC Wainwright & Co. | Andrew Fein56% | $4 → $2 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 40.32% | Chardan Capital | Keay Nakae54% | $2.5 → $2 | Maintains | Buy | Get Alert |
FAQ
What is the target price for ProQR Therapeutics (PRQR) stock?
The latest price target for ProQR Therapeutics (NASDAQ:PRQR) was reported by Chardan Capital on March 14, 2025. The analyst firm set a price target for $4.00 expecting PRQR to rise to within 12 months (a possible 180.64% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
The latest analyst rating for ProQR Therapeutics (NASDAQ:PRQR) was provided by Chardan Capital, and ProQR Therapeutics maintained their buy rating.
When was the last upgrade for ProQR Therapeutics (PRQR)?
The last upgrade for ProQR Therapeutics NV happened on October 29, 2024 when Raymond James raised their price target to $14. Raymond James previously had an outperform for ProQR Therapeutics NV.
When was the last downgrade for ProQR Therapeutics (PRQR)?
The last downgrade for ProQR Therapeutics NV happened on August 12, 2022 when Chardan Capital changed their price target from N/A to N/A for ProQR Therapeutics NV.
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on March 14, 2025 so you should expect the next rating to be made available sometime around March 14, 2026.
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a maintained with a price target of $4.00 to $4.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
